Toxic Shock Syndrome

Meet the patient

A 19-year-old student reaches the emergency department on day 2 of her period, drowsy and shivering. She has vomited and had diarrhoea all morning, her temperature is 39.4 deg C, her blood pressure is 84/50, and her skin — palms and soles included — is a diffuse, blanching sunburn red. A retained tampon is found the moment she is examined vaginally.[1][3]

Three facts are true at once, and each decides a life: she is in shock, she has a removable source, and the blood culture you have just sent will almost certainly be negative. Everything below exists to make those three facts automatic.[1]

Overview — what TSS actually is

TSS is a cytokine storm dressed up as an infection. A bacterial exotoxin switches off the normal specificity of the immune response, fires up to a third of all T-cells at once, and the resulting flood of IL-1, IL-2, TNF-alpha and IFN-gamma does the damage — vasodilation, capillary leak, myocardial stunning and multi-organ failure. The bacteria are only the trigger; your patient's own cytokines are the weapon.[2]

James Todd described the syndrome in 1978 in seven children with high fever, a sunburn-like rash, hypotension and multi-organ failure, from whose Staphylococcus aureus isolates a phage-group-I exotoxin was recovered. The toxin is now toxic-shock-syndrome toxin-1 (TSST-1). Within two years an epidemic of menstrual TSS struck young American women, traced to the Rely tampon — an ultra-high-absorbency product whose marketing promised you could "rely on it" and leave it in for days. Withdrawing Rely and regulating tampon absorbency cut menstrual TSS roughly tenfold.[4]

Today the picture has inverted. Non-menstrual staphylococcal TSS — surgical wounds, burns, postpartum uteri, nasal packing, skin sepsis — is now commoner than the menstrual form, and streptococcal TSS (STSS) from invasive Group A strep is the deadlier, rising cousin that walked in after COVID-19.[2][5]

The defining clinical tetrad is fixed in your head before you reach the bedside: fever over 38.9 deg C, a diffuse blanching 'sunburn' rash, hypotension (systolic BP at or under 90 mmHg in adults), and involvement of three or more organ systems. The diagnosis is clinical, by the CDC criteria reproduced verbatim below — organism isolation is not required for staphylococcal TSS, and the late desquamation of palms and soles at 1 to 2 weeks confirms it in retrospect.[1][3]

The single most important early action in staphylococcal TSS is removing the source — the tampon, sponge, packing or foreign body — which alone can abort the syndrome. In STSS the equivalent act is urgent surgical debridement of necrotising fasciitis, which is life-saving and must never wait for "stabilisation". Both need an anti-toxin antibiotic (clindamycin) on top of a beta-lactam, and IVIG in severe disease.[1][6]

Classification — staph versus strep, the fork that changes everything

TSS sorts along three axes: the organism, the staphylococcal source, and the CDC case status. The organism axis is the one that kills you if you misread it, because it sets the toxin, the source, the bacteraemia rate and the mortality in a single line.[1]

[1]

A confirmed staphylococcal case needs all five CDC criteria (fever over 38.9 deg C, diffuse macular rash, desquamation 1 to 2 weeks later, hypotension, and three or more organ systems) plus exclusion of other aetiologies. A probable case meets them all except desquamation — because the patient presents before it has happened, or dies before it does — or is missing one criterion. Isolation of S. aureus is not part of the case definition, and examiners test that fact repeatedly.[4][2]

The streptococcal case definition is structurally different and does require isolation of Group A strep from a normally sterile site in the 'definite' category (see Investigations). Hold the two definitions apart: staph needs three organ systems and no organism; strep needs two organ systems and the organism.[2]

Epidemiology — how common, and who is at risk

The 1979 to 1980 US menstrual epidemic peaked at about 13 cases per 100,000 menstruating women, traced to ultra-high-absorbency tampons — the Rely brand, made of carboxymethylcellulose and polyester foam. After Rely was withdrawn and tampon absorbency was regulated, menstrual TSS fell roughly tenfold to about 1 per 100,000. The Hajjeh CDC surveillance update (1979 to 1996) records both the fall and the simultaneous rise of non-menstrual disease; overall US staphylococcal TSS now sits around 3 to 5 per 100,000.[4]

Streptococcal TSS is rarer but far deadlier. Incidence is about 3 to 4 per 100,000 in developed countries, yet mortality runs 30 to 60 percent. A striking global surge in invasive Group A streptococcal disease and STSS swept the UK, Europe and the US in 2022 to 2023 in the wake of COVID-19, with children bearing a disproportionate share — possibly a susceptibility 'gap' from reduced GAS exposure during lockdowns.[5]

Risk factors for staphylococcal TSS — the colonised focus, not deep infection:[1]

• Tampon use — high-absorbency, prolonged or overnight, or a single tampon left in. The mechanism is biochemical: high-absorbency tampons bind magnesium, which derepresses TSST-1 production, and they create an oxygenated, protein-rich, neutral-to-alkaline vaginal environment that maximises toxin yield.[3]
• Barrier contraceptives — sponge, diaphragm, cervical cap.
• Surgical wounds — especially closed, clean-looking ones (the 'benign wound' trap).
• Postpartum uterus or wound; burns; skin and soft-tissue infection; nasal packing for epistaxis; foreign bodies (retained packing, mesh).
• Recent influenza or varicella — disrupts mucocutaneous barriers.

Risk factors for streptococcal TSS — invasive Group A strep, often from trivial skin injury:[1]

• Invasive soft-tissue infection — necrotising fasciitis, myositis, myonecrosis, cellulitis, pneumonia, postpartum sepsis, bone or joint infection.
• Minor trauma or bruise — the classic 'minor injury, catastrophic illness' history.
• Varicella (chickenpox) in children — a major gateway to GAS superinfection and STSS.
• NSAID use — controversial but commonly asked; may mask early symptoms.
• Immunocompromise, diabetes, alcoholism, IV drug use, advanced age, chronic skin disease.
• The post-COVID-19 surge as a population-level risk.[5]

[1]

Pathophysiology — one molecular event, the whole disease

Every clinical feature flows from a single trick: the superantigen bypass of antigen presentation. Understand it once and the rash, the shock, the negative blood cultures and the choice of clindamycin all become obvious.[1]

Etymology for viva gold: superantigen — from Latin super, "above" or "beyond", plus antigen. A superantigen acts "above" the normal rules of antigen specificity: it does not care which peptide sits in the groove, but bridges MHC class II and the T-cell receptor from the outside, firing a whole army of T-cells that were never meant to be called up.[2]

[1]

Normal antigen presentation is exquisitely specific. An antigen-presenting cell takes up antigen, chops it into peptides, loads one into the groove of MHC class II, and only the rare T-cell whose TCR CDR3 region recognises that exact peptide-MHC complex fires. At most about 0.01 percent — one in ten thousand — of all T-cells respond to any one antigen.[2]

The superantigen short-circuits this in two places at once. TSST-1, staphylococcal enterotoxins B and C (from S. aureus), and streptococcal pyrogenic exotoxins A and C (SpeA, SpeC, from Group A strep) bind the outer side surface of MHC class II — outside the peptide groove — and simultaneously the outer surface of the T-cell receptor beta-chain variable (V-beta) region, not the antigen-specific CDR3.[2]

Because the V-beta regions they grab are shared across large families of T-cells, a single superantigen activates 20 to 30 percent of all T-cells at once — a 1,000- to 10,000-fold jump over the normal 0.01 percent. The result is a cytokine storm of IL-1, IL-2, TNF-alpha and IFN-gamma, with IL-6.[3]

The four downstream cytokine effects you must be able to name

• Capillary leak — endothelial dysfunction and third-space albumin loss: the sunburn rash, oedema, pulmonary oedema, renal and hepatic dysfunction.
• Systemic vasodilation — profound, fluid-refractory hypotension.
• Myocardial depression — direct cytokine injury to cardiomyocytes.
• Multi-organ failure — AKI, hepatitis, ARDS, thrombocytopenia and DIC, rhabdomyolysis, encephalopathy without focal signs.[1]

The clinical syndrome is mediated entirely by host cytokines — and that single fact explains the two most-tested truths in TSS. Staphylococcal TSS is typically not bacteraemic: the toxin is made locally in the vagina or wound and absorbed, so the bacteria need never reach the bloodstream. Therefore blood cultures are negative in staphylococcal TSS, and organism isolation is not required for the diagnosis. Streptococcal TSS, by contrast, is bacteraemic in about 60 percent.[3]

The rash and the late desquamation are the same lesion at two time-points. Diffuse macular erythema (blanching, palms and soles included) is cytokine-driven dermal capillary leak and T-cell infiltration. The desquamation of palms, soles and fingertips at 1 to 2 weeks is simply the damaged stratum corneum being shed as a new layer regrows — which is why it is a late, confirmatory sign, never a presenting one.[2]

Why the 1980 epidemic tracked high-absorbency tampons is one biochemical sentence. TSST-1 production is maximised in a high-protein, oxygenated, neutral-to-alkaline environment — exactly what an ultra-absorbent tampon creates. Critically, high-absorbency tampons bind magnesium, and magnesium normally represses TSST-1 synthesis; remove the magnesium and toxin production is derepressed. The vaginal mucosa then absorbs the preformed toxin. That single fact explains both the epidemic and its collapse after regulation.[3]

About 90 percent of adults carry protective anti-TSST-1 antibodies from asymptomatic childhood colonisation with TSST-1-producing S. aureus. The roughly 10 percent who lack them are susceptible, and menstrual TSS recurs in about 30 percent of them without counselling. This is also the rationale for IVIG: pooled immunoglobulin carries high-titre anti-TSST-1 and anti-Spe antibodies that neutralise the circulating superantigen.[3]

Clinical presentation — fever, rash, shock, and a GI prodrome that fools you

TSS is acute and progressive over hours, dominated by a striking prodrome, the cardinal tetrad and evolving multi-organ failure. The tempo — hours, not days — and the staph-versus-strep discriminating features are the examiner's favourite test.[1]

Shared early features, both forms: high fever over 38.9 deg C; myalgia, headache, arthralgia, pharyngitis and conjunctivitis as a non-specific prodrome; abdominal pain, vomiting and diarrhoea at onset (a CDC criterion); hypotension with cool peripheries, mottling and tachycardia; altered mental state — disorientation or agitation without focal neurology (also a CDC criterion); and the diffuse, blanching, 'sunburn-like' rash over the whole body, palms and soles included. In dark skin the rash is subtle and easily missed.[1]

The classic trap: the GI prodrome is gastroenteritis until it is not. A young woman with fever, vomiting and diarrhoea gets labelled 'food poisoning' and sent home; the rash is put down to a viral exanthem and the hypotension is missed. Any febrile patient with vomiting, diarrhoea and a diffuse rash is TSS until proven otherwise.[1]

The classic menstrual vignette: a menstruating young woman using tampons, within 1 to 2 days of menses onset, with acute high fever, myalgia, sore throat, vomiting and diarrhoea, confusion and hypotension, and the diffuse sunburn rash — progressing over hours to multi-organ failure. Non-menstrual staphylococcal TSS is identical but the source is a surgical wound, postpartum wound, burn, skin infection, nasal packing or barrier contraceptive.[1]

The mucous-membrane signs are the ones that earn the diagnosis at the bedside: conjunctival hyperaemia, a 'strawberry tongue' (a white coating with red bumps that peels to leave a bright red tongue with prominent papillae), oropharyngeal hyperaemia and vaginal hyperaemia. This mucosal triad in any febrile, toxic patient should trigger TSS.[3]

Streptococcal TSS wears one of two faces. Most often (about 80 percent) there is a soft-tissue focus — necrotising fasciitis, myositis, myonecrosis, cellulitis or pneumonia — with the classic history of minor trauma or bruise followed by rapidly progressive, excruciatingly painful swelling, pain out of proportion to the visible findings, tense oedema, dusky or gangrenous skin, haemorrhagic bullae and cutaneous anaesthesia. Shock, renal failure, ARDS and coagulopathy follow over 24 to 48 hours. In about 20 percent there is no focus — just a flu-like illness that detonates into shock, the source an occult deep infection.[1]

The classic trap: STSS necrotising fasciitis is read as 'severe cellulitis' and the debridement is delayed. Pain out of proportion, cutaneous anaesthesia, haemorrhagic bullae and systemic toxicity are not cellulitis. Bacteraemia is present in about 60 percent of STSS versus uncommon in staphylococcal TSS — a discriminator examiners love.[6]

Atypical and special-context presentations to keep on the radar:[1]

• Postpartum TSS — within days of delivery; the uterus or wound may look uninfected. Explore the uterus, remove retained products or packing.
• Post-surgical TSS — often within 48 hours of surgery, far faster than a conventional wound infection; the wound looks clean and closed. Remove sutures and explore.
• Burn-associated TSS — a colonised burn wound with sudden deterioration and rash.
• Paediatric TSS — a skin focus or varicella lesions colonised by GAS; distinguish from Kawasaki disease.[5]
• Nasal-packing TSS — within 12 to 24 hours of packing for epistaxis; remove the packing at once.
• Elderly and immunocompromised — blunted fever (even hypothermia), confusion or collapse as the chief complaint, higher mortality, higher MRSA risk; broaden cover with vancomycin or linezolid.[1]

Differential diagnosis — fever, rash, shock: who else does this?

Frame the differential as fever plus rash plus hypotension plus multi-organ illness. Several conditions overlap with TSS and examiners test the distinction relentlessly.[1]

The discriminating features examiners expect, in a face-off table:[1]

[1]

The discriminator line: a blanching macular rash with shock and multi-organ failure and negative blood cultures is staphylococcal TSS; a non-blanching petechial rash with shock is meningococcaemia; a subacute fever over 5 days in a child under 5 without shock is Kawasaki.[1]

The most easily missed TSS is the post-surgical or postpartum case with a 'benign-looking' wound. The wound or uterus often appears uninfected and the diagnosis rests entirely on the systemic picture. Maintain a high index of suspicion: any patient with fever, a diffuse rash, hypotension and multi-organ involvement has TSS until proven otherwise.[1]

Clinical and bedside assessment — resuscitate first, then hunt the source

The bedside assessment is structured, time-critical and source-seeking, in that order. You resuscitate and look for the focus at the same time, not sequentially.[1]

ABCDE priorities: protect the airway if the patient is obtunded; high-flow oxygen and prepare to ventilate for ARDS or capillary-leak pulmonary oedema; two large-bore cannulae, aggressive crystalloid, vasopressors drawn up and an arterial line early; GCS and pupils, looking for CNS disorientation without focal signs, and exclude hypoglycaemia; then a full exposure including palms, soles, every mucous membrane, the genitalia, and every wound and burn — even closed and clean-looking ones.[1]

The focused source hunt is the highest-yield part of the assessment. Inspect every potential focus.[1]

• The vagina — remove any tampon; look for a retained sponge, diaphragm or foreign body; send for culture.
• Every surgical wound and burn, even if closed and clean (the trap); remove sutures and explore if suspicious.
• The postpartum uterus — bimanual and speculum examination for retained products, packing or abscess.
• The nose — if packed for epistaxis, remove the packing.
• The skin — cellulitis, abscess, varicella lesions, surgical-site infection.
• The soft tissues — actively elicit the signs of necrotising fasciitis: pain out of proportion, tense oedema, cutaneous anaesthesia, haemorrhagic bullae, skin necrosis, crepitus.[1]

Cardinal signs to elicit: diffuse blanching macular erythema including palms and soles; mucous-membrane hyperaemia (conjunctivae, oropharynx, strawberry tongue, vagina); hypotension (systolic at or under 90 mmHg or an orthostatic drop); and, if STSS is suspected, the necrotising-fasciitis signs above.[1]

The LRINEC score separates necrotising fasciitis from cellulitis — but only in one direction. Sum CRP, white-cell count, haemoglobin, sodium, creatinine and glucose:[1]

A LRINEC of 6 or more flags high risk of necrotising fasciitis (positive predictive value about 92 percent in the derivation cohort). The classic trap: LRINEC is insensitive. A high clinical suspicion overrides a 'low' score, and any patient with pain out of proportion and systemic toxicity goes to theatre regardless of the number.[6]

Examine for complications as you resuscitate: mental status (cerebral oedema, encephalopathy); urine output via Foley catheter, target at least 0.5 mL/kg/h, renal failure being a CDC criterion; perfusion via lactate, capillary refill and mottling; DIC (ooze from venepuncture sites, petechiae, purpura); and the heart for arrhythmia or myocardial depression.[1]

Investigations — the diagnosis is clinical; tests support, quantify, locate

TSS is a clinical diagnosis made on CDC criteria. No single confirmatory test exists at presentation. Investigations support the diagnosis, quantify organ failure, find the source and exclude mimics — and you never delay empiric therapy while waiting for results.[1]

CDC criteria for staphylococcal TSS (reproduce verbatim)

[1]

CDC criteria for streptococcal TSS (reproduce verbatim)

[1]

Note the structural differences, because they are an examiner staple: staphylococcal TSS requires three or more organ systems and no organism isolation, with the rash as a primary criterion; streptococcal TSS requires only two or more organ systems and does require Group A strep isolation, with soft-tissue necrosis able to substitute for organ failure. Bacteraemia is expected in STSS (about 60 percent) and uncommon in staphylococcal TSS.[2][6]

First-line blood tests: full blood count (leukocytosis with a left shift; thrombocytopenia under 100,000 per microL is a CDC criterion); urea and electrolytes (BUN or creatinine at least twice the upper limit of normal); liver function tests (bilirubin, AST or ALT at least twice the upper limit of normal); creatine kinase (at least twice the upper limit of normal); CRP and procalcitonin; coagulation including fibrinogen and D-dimer for DIC; lactate as a severity and clearance marker; venous gas for metabolic acidosis; glucose, calcium and albumin (hypocalcaemia is common in STSS, albumin is low from capillary leak).[1]

Microbiological specimens: blood cultures before antibiotics and repeated (bacteraemia expected in STSS, uncommon in staphylococcal TSS); wound, tissue and swab cultures from any focus; a vaginal swab and the removed tampon for S. aureus and TSST-1 testing; a throat swab for GAS; urine for Group A strep antigen and microscopy for sterile pyuria (a CDC criterion).[1]

TSST-1 antibody testing is not useful acutely — it takes weeks and only confirms a diagnosis in retrospect — but about 90 percent of adults have protective titres, and its absence identifies the susceptible, recurrent patient.[3]

Imaging and bedside tests to exclude mimics: chest X-ray for ARDS, pulmonary oedema or pneumonia as a source; ultrasound or CT of soft tissue for an occult focus (gas in clostridial myonecrosis, fascial thickening with fat stranding in necrotising fasciitis); echocardiography for myocardial depression; a blood film for atypical lymphocytes and eosinophilia (DRESS); and meningococcal PCR and culture, with RMSF, leptospirosis and viral serology as the CDC criteria require.[1]

Management — resuscitate, remove the source, suppress the toxin

TSS is a time-critical emergency; deliver the resuscitation bundle concurrently, not sequentially.[1]

[1]

The time-critical bundle, in the order of what kills first:[1]

1. ABCDE — airway protection if obtunded; high-flow oxygen; two large-bore cannulae; full monitoring.
2. Aggressive IV crystalloid — 10 to 20 mL/kg boluses repeated, up to 30 mL/kg in the first hour, titrated to MAP at least 65 mmHg, urine output at least 0.5 mL/kg/h and lactate clearance. Severe capillary leak means very large volumes — often 5 to 10 L — are needed; reassess after each bolus for pulmonary oedema.
3. Immediate source control — remove the tampon, sponge, diaphragm or foreign body at once (this alone can abort staphylococcal TSS); inspect and debride any wound; drain abscesses; remove nasal packing; explore the postpartum uterus. In STSS do not wait to stabilise before surgery — the patient stabilises only after source control.[6]
4. Empirical IV antibiotics within 1 hour covering staph (including MRSA) and strep and suppressing toxin — clindamycin is the cornerstone (see regimens below).
5. Vasopressors for refractory shock — noradrenaline first-line to MAP at least 65 mmHg; add vasopressin if refractory; consider adrenaline if myocardial depression predominates. Do not withhold vasopressors to give more fluid in refractory shock.
6. IVIG in severe or refractory disease — 1 to 2 g/kg as a single dose (or 0.5 g/kg/day for 4 days) for refractory shock, deepening organ failure, or any STSS.
7. Supportive measures — ventilation for ARDS, renal replacement therapy for renal failure, glucose and electrolyte control, stress-ulcer and VTE prophylaxis, temperature control.

Management — definitive therapy and the anti-toxin principle

Definitive therapy builds on resuscitation with anti-toxin treatment, source control, IVIG and organ support, and the escalation triggers are explicit.[1]

[1]

The antibiotic regimen — cover both organisms and suppress the toxin

The empirical regimen must cover staphylococcal (including MRSA) and streptococcal disease and suppress toxin production. Clindamycin is the cornerstone: uniquely among these agents, it suppresses TSST-1 and Spe synthesis by inhibiting 50S ribosomal protein synthesis. Penicillin alone may transiently increase toxin release by lysing bacteria, which is why a beta-lactam is always combined with clindamycin.[3][6]

[1]

Why clindamycin is the cornerstone. It inhibits the 50S ribosomal subunit and so suppresses bacterial exotoxin synthesis — cutting TSST-1 and Spe production by about 90 percent even when organisms remain viable. It also suppresses M-protein synthesis in Group A strep, and it is unaffected by the Eagle effect that cripples penicillin in high-inoculum, stationary-phase GAS infection (where penicillin-binding proteins are down-regulated). Penicillin, oxacillin and nafcillin, by contrast, can transiently increase toxin release as they lyse bacteria — so a beta-lactam always rides with clindamycin. This is one of the most frequently tested facts in TSS.[3][6]

Why linezolid is the MRSA alternative. A 50S protein-synthesis inhibitor (oxazolidinone), linezolid suppresses toxin production and covers MRSA in a single agent — dose 600 mg IV q12h. Cautions: it is a weak MAO-A inhibitor (serotonin syndrome risk with SSRIs and serotonergic drugs), and prolonged use brings thrombocytopenia, anaemia and peripheral or optic neuropathy.[1]

IVIG — dose and rationale. Pooled human immunoglobulin delivers a bolus of anti-TSST-1 and anti-Spe antibodies that neutralise circulating superantigen and dampen T-cell and macrophage activation. Dose 1 to 2 g/kg IV over 12 to 24 hours (or 0.5 g/kg/day for 4 days). Evidence is strongest for STSS (one small RCT, Darenberg 2003, showed a trend to mortality benefit; observational data support staphylococcal TSS refractory to standard care). Indications are refractory shock, deepening organ failure, or any STSS — but do not delay source control, antibiotics and vasopressors while waiting for it.[2][6]

Surgical principles for STSS with necrotising fasciitis

Surgery is life-saving in STSS with necrotising fasciitis and must never wait for stabilisation — the patient stabilises only after source control. The principles:[6]

1. Urgent exploration within hours — incise over the point of maximal tenderness and dissect down to and along fascial planes.
2. Debride all necrotic tissue to bleeding viable tissue — necrotic fascia does not bleed and separates easily, with 'dishwater' fluid and grey, friable fascia.
3. Re-look in theatre at 24 to 48 hours — necrosis usually extends beyond the first debridement; plan the return.
4. Send tissue for culture and adjust antibiotics accordingly.
5. Amputation may be required for limb gangrene — a life-saving act, not a failure.[1]

Management of complications

Manage the organ failures as they declare themselves: ARDS with lung-protective ventilation (tidal volume 6 mL/kg ideal body weight, plateau pressure under 30 cmH2O), prone positioning and neuromuscular blockade in severe cases; DIC with platelets and fresh-frozen plasma if bleeding (do not treat asymptomatic laboratory DIC); renal failure with renal replacement therapy, continuous if unstable; rhabdomyolysis with fluids to a urine output of 1 to 2 mL/kg/h; myocardial depression with dobutamine or adrenaline (milrinone if on vasopressors); cerebral oedema with 30-degree head elevation, normocapnia and osmotic therapy if herniation threatens.[1]

Prevention and patient-safety counselling

Counsel every recovered patient on tampon hygiene, because recurrence is preventable and education is the single most effective intervention. Use the lowest-absorbency tampon that meets needs, change every 4 to 8 hours, avoid overnight use, and use no tampons at all after an episode of menstrual TSS; avoid barrier contraceptives (sponge, diaphragm) after staphylococcal TSS. The recurrence risk for menstrual TSS without counselling is about 30 percent. Consider oral clindamycin eradication therapy for the roughly 10 percent of adults who lack anti-TSST-1 antibodies and recur.[4]

How TSS patients come to harm — the preventable list

The deaths in TSS are preventable, and almost all cluster on the same errors. Name them, because naming them is how you avoid them.[1]

• Missing the diagnosis behind a 'benign' closed wound or a 'gastroenteritis' prodrome — the wound looks clean and the GI symptoms read as food poisoning; the rash and hypotension are the tell.[1]
• Treating for sepsis without an anti-toxin agent — penicillin or oxacillin alone may transiently increase toxin release; the most common pharmacological error is omitting clindamycin.[3][6]
• Failing to remove the source — the tampon, sponge, packing or foreign body left in place while antibiotics are drawn up; removal alone can abort staphylococcal TSS.[3]
• Reading STSS necrotising fasciitis as 'severe cellulitis' and delaying debridement — pain out of proportion overrides a low LRINEC; theatre now.[6]
• Delaying surgery in STSS to 'stabilise' the patient — the patient stabilises only after source control, never before it.[6]
• Waiting for blood cultures in staphylococcal TSS — they are usually negative and the diagnosis is clinical; delaying treatment for a result costs lives.[3]
• Withholding vasopressors while pouring in fluid — pulmonary oedema and ARDS from overload.[1]
• Under-dosing IVIG (1 to 2 g/kg, not 0.4 g/kg) or omitting MRSA cover when MRSA is plausible.[1]

Specific subtypes and scenarios

Menstrual TSS — the classic vignette. A menstruating young woman within 1 to 2 days of menses onset, high fever, myalgia, vomiting, diarrhoea, confusion, hypotension and the sunburn rash. TSST-1-producing S. aureus colonises the vagina and the toxin is absorbed across the mucosa. Remove the tampon immediately (this alone can abort the syndrome), resuscitate, give clindamycin plus flucloxacillin, IVIG if severe, and counsel on recurrence prevention.[3]

Non-menstrual staphylococcal TSS — now the commoner form. The source is a surgical wound (often closed and benign-looking — the trap), a postpartum wound, a burn, a skin or soft-tissue infection, nasal packing, a barrier contraceptive or a foreign body. Management is identical: find and remove the source. The wound may need opening and exploration even when it looks clean — the diagnosis is the systemic picture.[1]

Streptococcal TSS — the deadly cousin. Group A strep deep soft-tissue infection (necrotising fasciitis in about 50 percent, myositis, cellulitis) or a non-focal flu-like illness; bacteraemia in about 60 percent; mortality 30 to 60 percent. Management is urgent surgical debridement within hours, benzylpenicillin plus clindamycin, IVIG 1 to 2 g/kg and organ support. Surgery is life-saving and must not be delayed.[6]

Paediatric TSS — suspect it in any febrile child with rash and shock. The focus is often a skin infection or varicella lesions colonised by GAS. The Kawasaki overlap is the trap: Kawasaki is in children under 5, is subacute (fever over 5 days), has no shock and shows thrombocytosis after day 7 (TSS has thrombocytopenia early), and carries a coronary-aneurysm risk (give IVIG 2 g/kg plus aspirin for Kawasaki). Use weight-based fluids (10 to 20 mL/kg boluses) and weight-based antibiotics, and involve PICU.[5]

Postpartum and post-surgical TSS. The uterine or wound focus often looks uninfected — the diagnosis is systemic, the source found only on direct inspection. Remove sutures, explore the uterus, remove any retained products or packing. High suspicion for any postpartum or post-surgical patient with fever, rash, shock and multi-organ involvement, even with a clean wound.[1]

Recurrent TSS. Patients lacking anti-TSST-1 antibody (about 10 percent of adults) are susceptible to recurrence (about 30 percent for menstrual TSS without counselling). Counsel on tampon and barrier avoidance; some advocate oral clindamycin eradication therapy to clear S. aureus carriage.[3]

Complications and prognosis

Early complications are the cytokine storm writ large: refractory shock, ARDS, AKI needing renal replacement therapy, DIC with bleeding and microvascular thrombosis, rhabdomyolysis, myocarditis with myocardial depression, hepatic failure, cerebral oedema and encephalopathy, gangrene and amputation in STSS, and multi-organ death.[1]

Late complications declare themselves on a clock: full-thickness desquamation of palms and soles at 1 to 2 weeks; reversible alopecia and nail shedding (Beau lines, onychomadesis) at 2 to 3 months; chronic kidney disease; and persistent neuropsychiatric sequelae — cognitive impairment, depression, anxiety and fatigue — for months.[1]

Case-fatality is the single number that separates the two diseases. Staphylococcal TSS dies at 3 to 5 percent with modern ICU care; streptococcal TSS dies at 30 to 60 percent. Predictors of fatal STSS are advanced age, comorbidity (diabetes, immunocompromise), deep tissue necrosis, delay to surgery, bacteraemia, renal failure, ARDS and hypocalcaemia.[2][6]

Disposition is simple in principle: all suspected TSS go to ICU (level 3). STSS and any patient on vasopressors, ventilation or renal replacement therapy need a tertiary centre with surgical and intensive-care capability. Mobilise the sepsis team and infectious diseases early, and surgery immediately if necrotising fasciitis is suspected.[1]

Recovery and follow-up. The acute phase (hours to days) carries the greatest mortality risk; desquamation follows at 1 to 2 weeks; full clinical recovery takes weeks to months, with nail and hair changes at 2 to 3 months. Recurrence risk for menstrual TSS without counselling is about 30 percent — counsel on tampon and barrier avoidance, consider serology to find the anti-TSST-1-negative patient, and notify public health where mandated.[4]

Special populations

[1]

Paediatrics. Suspect TSS in any febrile child with rash and shock. Weight-based fluids (10 to 20 mL/kg boluses) and antibiotics — clindamycin 10 mg/kg IV q8h, flucloxacillin 50 mg/kg IV q6h, vancomycin 15 mg/kg IV q6h for MRSA, benzylpenicillin 50 mg/kg IV q6h for GAS. Distinguish Kawasaki (under 5 years, fever over 5 days, no shock, thrombocytosis after day 7, coronary aneurysm — IVIG 2 g/kg plus aspirin). Varicella-associated STSS is common; treat aggressively and involve PICU.[5]

Pregnancy and postpartum. Postpartum TSS (vaginal or caesarean wound) presents within days of delivery; the uterus or wound may look uninfected, so explore the uterus and remove retained products or packing. Pregnancy itself does not change management; deliver if chorioamnionitis is the source. Clindamycin, flucloxacillin, benzylpenicillin and vancomycin are safe in pregnancy and breastfeeding.[1]

Elderly and immunocompromised. Fever may be blunted or absent (even hypothermia); the presentation is atypical — confusion, collapse, falls. Mortality is higher, especially in STSS, and MRSA risk is higher, so broaden cover with vancomycin or linezolid. Comorbidities (diabetes, renal failure, immunosuppression) worsen outcome and complicate dosing.[2]

Anticoagulated, dialysis-dependent and comorbid. Manage DIC if present (platelets and plasma for bleeding; do not treat asymptomatic laboratory DIC). Adjust antibiotics for renal impairment — clindamycin needs none; vancomycin is trough-guided; linezolid needs none but watch for cytopenias with prolonged use. Vasopressors are safe in dialysis patients — do not withhold them. Give VTE prophylaxis; the patient is critically ill and at high VTE risk.[1]

Evidence, guidelines and regional differences

Landmark history. Todd (1978) first described TSS in seven children. The 1979 to 1980 US tampon epidemic (Rely brand) peaked at about 13 per 100,000 menstruating women; the fall after tampon-absorbency regulation is documented in the Hajjeh CDC surveillance update of 1979 to 1996. The CDC case definition for staphylococcal TSS was set in 1980 to 1981 and refined; the consensus definition for streptococcal TSS followed in 1993.[4][2]

IDSA and Stevens guidance on invasive GAS recommends clindamycin plus penicillin (clindamycin suppresses M-protein and Spe and dodges the Eagle effect), IVIG for STSS, and urgent surgical debridement for necrotising fasciitis.[6]

The IVIG controversy is real but does not change the bedside. Evidence is observational with one small RCT (Darenberg 2003) showing a trend to mortality benefit in STSS; guidelines recommend IVIG (1 to 2 g/kg) but dosing varies and the evidence quality is moderate. The biological rationale is strong — pooled immunoglobulin carries anti-TSST-1 and anti-Spe antibodies.[2]

The 2022 to 2023 post-COVID-19 iGAS surge was striking and global — the UK, Europe, the US and elsewhere saw a jump in invasive Group A streptococcal disease and STSS, with children disproportionately affected. Public-health alerts followed (UKHSA, WHO, CDC). The leading explanation — reduced population GAS exposure during pandemic lockdowns leaving a susceptibility gap — remains under investigation.[5]

Regional deltas. In India and South Asia tampon use is uncommon, so menstrual TSS is rare and postpartum, surgical, burn-related and STSS from skin sepsis dominate; IVIG availability and cost vary and often limit use. UK, US, WHO and ICMR guidance broadly converge on the same backbone: source control plus clindamycin plus beta-lactam plus MRSA cover plus IVIG. CDC and IDSA definitions anchor international practice.[2]

The mantra, and the pearls that decide an answer

The mantra: fever, rash, shock, three organs — remove the source, give the anti-toxin, support the cytokine storm.[1][2][3][6]

Ward-round test — three stems, thirty seconds each

Stem 1 — the menstruating woman from the top of the topic (answer)

The 19-year-old with day-2 menses, a retained tampon, fever of 39.4 deg C, sunburn rash on palms and soles, vomiting and diarrhoea, confusion and a blood pressure of 84/50. What is it, and what do you do in the next 15 minutes? Model: This is staphylococcal TSS — fever over 38.9 deg C, diffuse blanching rash, hypotension and multi-organ involvement in a menstruating woman with a tampon. The blood culture will almost certainly be negative and S. aureus isolation is not required for the diagnosis. First, remove the tampon at once — it alone can abort the syndrome. Resuscitate with aggressive crystalloid (10 to 20 mL/kg boluses to MAP at least 65 mmHg and urine output at least 0.5 mL/kg/h), start clindamycin 600 to 900 mg IV q8h plus flucloxacillin 2 g IV q6h (add vancomycin or linezolid if MRSA is plausible), give IVIG 1 to 2 g/kg if shock is refractory or organs are failing, escalate to noradrenaline for fluid-refractory shock, and admit to ICU. Do not wait for cultures. Counsel on recurrence prevention once she recovers.[1][3]

Stem 2 — the post-surgical patient with shock and a clean wound (answer)

A 52-year-old, 36 hours after an uncomplicated hernia repair, is febrile at 39 deg C, hypotensive at 82/50, confused, and has a diffuse blanching rash. The surgical wound is dry, closed and pristine, and the team calls it sepsis of unknown source. What is the trap and the right move? Model: This is non-menstrual staphylococcal TSS with the 'benign wound' trap. The wound looks clean and closed precisely because the syndrome is toxin-mediated and systemic, not a local infection — the diagnosis is the patient, not the wound. Open the wound and explore it, remove sutures and any foreign body, send cultures, and start clindamycin 600 to 900 mg IV q8h plus flucloxacillin 2 g IV q6h (vancomycin or linezolid if MRSA is plausible given the healthcare exposure), resuscitate aggressively, add IVIG 1 to 2 g/kg if refractory, and admit to ICU. The classic error is treating it as generic sepsis without an anti-toxin agent and leaving the wound closed.[1][3]

Stem 3 — the severe cellulitis with bacteraemia and shock (answer)

A 60-year-old diabetic scraped his shin two days ago. Now the leg is swollen, exquisitely tender and dusky, he is confused, blood pressure is 78/46, and blood cultures grow Group A strep. LRINEC is 4. What is this, and what is the single most important intervention? Model: This is streptococcal TSS with necrotising fasciitis — invasive Group A strep from a skin portal, bacteraemic (as STSS is in about 60 percent), in shock. Pain out of proportion with systemic toxicity overrides the LRINEC of 4. The single most important intervention is urgent surgical debridement within hours — the patient stabilises only after source control, never before it. Give benzylpenicillin 2.4 g IV q4 to 6h plus clindamycin 900 mg IV q8h (clindamycin suppresses Spe and M-protein and dodges the Eagle effect), add IVIG 1 to 2 g/kg, resuscitate and support failing organs. Mortality is 30 to 60 percent; delay to surgery is the modifiable killer.[6][1]

References

1. [1]Gottlieb M, Long B, Koyfman A. The Evaluation and Management of Toxic Shock Syndrome in the Emergency Department: A Review of the Literature J Emerg Med, 2018.PMID 29366615
2. [2]Lappin E, Ferguson AJ. Gram-positive toxic shock syndromes Lancet Infect Dis, 2009.PMID 19393958
3. [3]Silversides JA, Lappin E, Ferguson AJ. Staphylococcal toxic shock syndrome: mechanisms and management Curr Infect Dis Rep, 2010.PMID 21308522
4. [4]Hajjeh RA, Reingold A, Weil A, Shutt K, Schuchat A, Perkins BA. Toxic shock syndrome in the United States: surveillance update, 1979 1996 Emerg Infect Dis, 1999.PMID 10603216
5. [5]Gaensbauer JT, Birkholz M, Smit MA, Garcia R, Todd JK. Epidemiology and Clinical Relevance of Toxic Shock Syndrome in US Children Pediatr Infect Dis J, 2018.PMID 29601458
6. [6]Stevens DL, Bryant AE, Goldstein EJ. Necrotizing Soft Tissue Infections Infect Dis Clin North Am, 2021.PMID 33303335